Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

LAB

Standard BioTools Inc

Sep 20 • 04:00PM ET

2.01

Dollar change -0.10
Percentage change -4.74	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI ARKG IWM VXF IWN VTWO VHT IWC IWO DFAC

Index	RUT	P/E	-	EPS (ttm)	-0.90	Insider Own	3.32%	Shs Outstand	371.15M	Perf Week	-2.43%
Market Cap	746.01M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	314.17%	Shs Float	358.85M	Perf Month	3.61%
Income	-164.66M	PEG	-	EPS next Q	-0.09	Inst Own	72.58%	Short Float	6.20%	Perf Quarter	4.15%
Sales	136.30M	P/S	5.47	EPS this Y	56.74%	Inst Trans	-1.58%	Short Ratio	6.87	Perf Half Y	-25.56%
Book/sh	1.37	P/B	1.46	EPS next Y	46.72%	ROA	-22.29%	Short Interest	22.23M	Perf Year	-27.70%
Cash/sh	1.06	P/C	1.89	EPS next 5Y	-8.06%	ROE	-59.79%	52W Range	1.21 - 3.04	Perf YTD	-9.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.72%	ROI	-30.48%	52W High	-33.88%	Beta	1.58
Dividend TTM	-	Quick Ratio	3.53	Sales past 5Y	-0.06%	Gross Margin	46.67%	52W Low	66.12%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	3.88	EPS Y/Y TTM	15.31%	Oper. Margin	-83.01%	RSI (14)	50.70	Volatility	6.63% 6.64%
Employees	539	Debt/Eq	0.18	Sales Y/Y TTM	29.25%	Profit Margin	-120.81%	Recom	1.00	Target Price	3.17
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	43.31%	Payout	-	Rel Volume	1.49	Prev Close	2.11
Sales Surprise	-22.89%	EPS Surprise	-44.06%	Sales Q/Q	34.48%	Earnings	Jul 31 AMC	Avg Volume	3.24M	Price	2.01
SMA20	-1.54%	SMA50	1.26%	SMA200	-11.61%	Trades		Volume	4,829,512	Change	-4.74%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Sep-18-24 08:00AM	Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) (GlobeNewswire)
Aug-26-24 08:00AM	Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-23-24 06:03PM	Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors (Barrons.com) +9.74%
Aug-06-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 09:14AM	Q2 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -36.61%
09:57PM	Loading…
Jul-31-24 09:57PM	LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024 (InvestorPlace)
05:40PM	Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Standard BioTools Announces Senior Leadership Changes (GlobeNewswire)
04:01PM	Standard BioTools Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:01AM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire)
May-28-24 04:01PM	Standard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers (GlobeNewswire)
May-22-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-24 08:00AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:59PM	Loading…
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49% +7.59%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
04:05PM	Loading…
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)
Nov-09-23 05:54AM	Q3 2023 Somalogic Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
Nov-08-23 12:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:52AM	Q3 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:23PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:30AM	Standard BioTools to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-25-23 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) -10.50%
Oct-10-23 10:22AM	Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm (GlobeNewswire)
Oct-05-23 02:42PM	Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm (PR Newswire)
Oct-04-23 06:49PM	Why SomaLogic Stock Dived by 10% on Wednesday (Motley Fool) -22.22%
08:52AM	Standard BioTools to Combine with SomaLogic in $1 Billion Merger (Bloomberg)
08:00AM	Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools (GlobeNewswire)
Aug-09-23 09:06AM	Q2 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) +7.56%
Aug-08-23 05:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-23 04:05PM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 07:33AM	Strong week for Standard BioTools (NASDAQ:LAB) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
Jun-14-23 07:30AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-13-23 01:30PM	With 45% ownership, Standard BioTools Inc. (NASDAQ:LAB) has piqued the interest of institutional investors (Simply Wall St.)
May-25-23 04:05PM	Standard BioTools to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:11AM	With Standard BioTools Up 29%, Insider Buyers Count Their Returns \ (Simply Wall St.)
06:05AM	Jeffrey Black Spends US$194k On Standard BioTools Stock \ (Simply Wall St.)
May-18-23 07:30AM	Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System (GlobeNewswire) +12.05%
May-15-23 07:30AM	Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
May-10-23 02:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.85%
06:16AM	Q1 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 06:11PM	Standard BioTools: Q1 Earnings Snapshot (AP Finance)
04:05PM	Standard BioTools Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 04:30PM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-20-23 05:03PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-23 10:42AM	Standard BioTools Inc.'s (NASDAQ:LAB) Low P/S No Reason For Excitement (Simply Wall St.)
Apr-17-23 08:30AM	Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology (GlobeNewswire)
Mar-22-23 08:30AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-23 08:30AM	Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors (GlobeNewswire)
Mar-14-23 08:30AM	Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire) +11.05%
Mar-01-23 04:05PM	Standard BioTools to Present at 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-23 08:30AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-17-23 06:43PM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-15-23 06:01PM	How a Peninsula biotech tools company looks to corral 'one-trick ponies' (American City Business Journals)
Feb-14-23 04:05PM	Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook (GlobeNewswire)
Feb-03-23 05:30AM	The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable (Simply Wall St.)
Jan-31-23 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Jan-09-23 08:30AM	Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update (GlobeNewswire) +6.45%
Jan-03-23 08:30AM	Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer (GlobeNewswire) +11.11%
Dec-24-22 08:01AM	Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year (Simply Wall St.)
Nov-28-22 08:30AM	Standard BioTools Authorizes up to $20 Million of Share Repurchases (GlobeNewswire) +10.00%
Nov-22-22 09:20AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-22 05:02AM	Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) (Simply Wall St.) +26.42%
Nov-08-22 04:05PM	Standard BioTools Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems (GlobeNewswire) -9.82%
Oct-25-22 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results (GlobeNewswire) +14.95%

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taich Adam	Former Officer	Sep 09 '24	Proposed Sale	2.00	45,851	91,725		Sep 09 03:19 PM
Casdin Partners Master Fund, L	Director	Aug 27 '24	Buy	2.19	250,000	546,750	54,025,821	Aug 29 08:30 PM
Casdin Partners Master Fund, L	Director	Aug 23 '24	Buy	2.13	292,100	620,975	53,625,821	Aug 26 08:10 PM
Casdin Partners Master Fund, L	Director	Aug 22 '24	Buy	1.96	307,900	602,807	53,333,721	Aug 26 08:10 PM
Casdin Partners Master Fund, L	Director	Aug 26 '24	Buy	2.15	150,000	322,455	53,775,821	Aug 26 08:10 PM
Casdin Partners Master Fund, L	Director	Aug 21 '24	Buy	1.90	500,000	951,950	53,025,821	Aug 21 08:47 PM
Casdin Partners Master Fund, L	Director	Aug 20 '24	Buy	1.87	500,000	936,700	52,525,821	Aug 21 08:47 PM
Casdin Partners Master Fund, L	Director	Aug 19 '24	Buy	1.85	250,000	463,225	52,025,821	Aug 21 08:47 PM
Black Jeffrey G.	SVP & Chief Financial Officer	Aug 15 '24	Option Exercise	0.00	13,157	0	432,993	Aug 19 05:30 PM
Casdin Partners Master Fund, L	Director	Aug 14 '24	Buy	1.59	1,200,000	1,913,520	51,775,821	Aug 16 07:52 PM
Casdin Partners Master Fund, L	Director	Aug 13 '24	Buy	1.62	550,000	890,560	50,575,821	Aug 13 08:15 PM
Casdin Partners Master Fund, L	Director	Aug 09 '24	Buy	1.61	525,408	848,481	49,525,821	Aug 13 08:15 PM
Casdin Partners Master Fund, L	Director	Aug 12 '24	Buy	1.64	500,000	820,600	50,025,821	Aug 13 08:15 PM
Casdin Partners Master Fund, L	Director	Aug 08 '24	Buy	1.64	569,562	932,601	49,000,413	Aug 09 09:34 PM
Casdin Partners Master Fund, L	Director	Aug 07 '24	Buy	1.57	500,000	786,200	48,430,821	Aug 09 09:34 PM
Casdin Partners Master Fund, L	Director	Aug 02 '24	Buy	1.63	1,000,000	1,631,900	47,730,821	Aug 06 09:58 PM
Casdin Partners Master Fund, L	Director	Aug 05 '24	Buy	1.58	200,000	316,780	47,930,821	Aug 06 09:58 PM
Casdin Partners Master Fund, L	Director	May 23 '24	Buy	2.60	100,000	260,000	46,075,821	May 28 08:45 PM
Casdin Partners Master Fund, L	Director	May 21 '24	Buy	2.56	350,000	895,930	45,825,821	May 22 07:53 PM
Casdin Partners Master Fund, L	Director	May 22 '24	Buy	2.58	150,000	387,735	45,975,821	May 22 07:53 PM
Casdin Partners Master Fund, L	Director	May 20 '24	Buy	2.58	100,000	258,130	45,475,821	May 22 07:53 PM
Casdin Partners Master Fund, L	Director	May 15 '24	Buy	2.57	500,000	1,282,550	44,523,749	May 17 08:11 PM
Casdin Partners Master Fund, L	Director	May 16 '24	Buy	2.54	500,000	1,270,950	45,023,749	May 17 08:11 PM
Casdin Partners Master Fund, L	Director	May 17 '24	Buy	2.56	352,072	902,044	45,375,821	May 17 08:11 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 15 '24	Option Exercise	0.00	52,631	0	138,615	May 16 09:07 PM
Egholm Michael	President & CEO	Apr 04 '24	Option Exercise	0.00	196,512	0	422,030	Apr 05 06:59 PM
Kim Hanjoon Alex	Chief Operating Officer	Apr 04 '24	Option Exercise	0.00	70,183	0	140,366	Apr 05 06:58 PM
Casdin Partners Master Fund, L	Director	Mar 04 '24	Buy	2.57	250,000	642,500	11,496,525	Mar 06 07:20 PM
Casdin Partners Master Fund, L	Director	Mar 05 '24	Buy	2.62	1,403	3,669	11,497,928	Mar 06 07:20 PM

Open in Screener

WGS

GeneDx Holdings Corp

Sep 20 • 04:00PM ET

40.40

Dollar change -0.25
Percentage change -0.62	%

Healthcare • Health Information Services • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

WGS GeneDx Holdings Corp daily Stock Chart

Held by: IWM VTI VXF IWN VTWO VFMO ITOT IWC CPAI AVSC

Index	RUT	P/E	-	EPS (ttm)	-4.50	Insider Own	30.14%	Shs Outstand	25.98M	Perf Week	6.68%
Market Cap	1.09B	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-6.49%	Shs Float	18.82M	Perf Month	17.10%
Income	-117.47M	PEG	-	EPS next Q	-0.26	Inst Own	58.62%	Short Float	11.63%	Perf Quarter	47.12%
Sales	243.66M	P/S	4.47	EPS this Y	76.59%	Inst Trans	-11.56%	Short Ratio	5.12	Perf Half Y	340.09%
Book/sh	7.21	P/B	5.61	EPS next Y	96.55%	ROA	-27.15%	Short Interest	2.19M	Perf Year	963.16%
Cash/sh	3.97	P/C	10.19	EPS next 5Y	-	ROE	-47.93%	52W Range	1.16 - 40.92	Perf YTD	1369.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-38.26%	52W High	-1.27%	Beta	2.36
Dividend TTM	-	Quick Ratio	2.22	Sales past 5Y	5.08%	Gross Margin	47.32%	52W Low	3382.76%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	2.38	EPS Y/Y TTM	88.09%	Oper. Margin	-32.55%	RSI (14)	68.04	Volatility	6.13% 6.47%
Employees	1000	Debt/Eq	0.61	Sales Y/Y TTM	3.06%	Profit Margin	-48.21%	Recom	2.00	Target Price	40.83
Option/Short	Yes / Yes	LT Debt/Eq	0.58	EPS Q/Q	40.37%	Payout	-	Rel Volume	2.05	Prev Close	40.65
Sales Surprise	18.89%	EPS Surprise	70.10%	Sales Q/Q	44.77%	Earnings	Jul 30 AMC	Avg Volume	427.68K	Price	40.40
SMA20	16.13%	SMA50	20.47%	SMA200	132.11%	Trades		Volume	877,564	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Aug-12-24 04:05PM	GeneDx to Participate in Fall Investor Conferences (Business Wire)
Aug-09-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-30-24 08:57PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) -10.57% +8.60%
04:05PM	GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
04:05PM	GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients (Business Wire)
12:00PM	Loading…
Jul-12-24 12:00PM	All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 04:05PM	GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 (GlobeNewswire) +9.36%
Jul-06-24 07:00AM	7 Small-Cap Stocks With Massive Potential Returns (InvestorPlace)
Jun-10-24 08:30AM	GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients (GlobeNewswire)
Jun-05-24 07:00AM	GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients (GlobeNewswire) +13.20%
May-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-24 02:20PM	Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More (Insider Monkey) +13.52%
Apr-30-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +55.18%
Apr-29-24 08:55PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	GeneDx Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-23-24 08:30AM	GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset (GlobeNewswire) +15.50%
Apr-04-24 04:05PM	GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 (GlobeNewswire) +10.39%
Mar-21-24 09:55AM	Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher (Zacks) +7.87%
Mar-14-24 08:30AM	GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics (GlobeNewswire)
Feb-26-24 04:05PM	GeneDx to Participate in 44th Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-24 08:33AM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.63%
Feb-20-24 04:26PM	GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 (GlobeNewswire)
Feb-01-24 04:30PM	GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 (GlobeNewswire)
Jan-24-24 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.98%
Jan-08-24 08:55AM	GeneDx Announces Preliminary 2023 Financial Results (GlobeNewswire) +40.36%
Dec-01-23 08:30AM	GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy (GlobeNewswire)
Nov-28-23 04:05PM	GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +12.80%
Nov-20-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -13.13%
Nov-10-23 09:55AM	Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now (Zacks) -13.61%
12:10PM	Loading…
Nov-05-23 12:10PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 08:19AM	Q3 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM	GeneDx Holdings Corp (WGS) Reports Q3 2023 Financial Results (GuruFocus.com) -8.56%
04:05PM	GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-09-23 04:05PM	GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023 (GlobeNewswire)
Sep-22-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-23 01:01PM	Insider Sell: CEO Katherine Stueland Sells 2,675 Shares of GeneDx Holdings Corp (GuruFocus.com) -5.03%
Sep-11-23 08:00AM	GeneDx Announces Evolution of Executive Leadership Team (GlobeNewswire)
Sep-06-23 08:00AM	GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced (GlobeNewswire)
Aug-21-23 07:00AM	GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine (GlobeNewswire)
Aug-09-23 08:16AM	PacBio (PACB) Inks Research Collaboration for Genome Sequencing (Zacks) -12.63%
07:59AM	Q2 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 08:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-23 08:00AM	PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care (GlobeNewswire) -6.30%
Jul-19-23 07:05AM	GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options (GlobeNewswire) +6.48%
Jul-18-23 04:05PM	GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (GlobeNewswire)
Jun-28-23 07:00AM	GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundations Mitochondrial Medicine Symposium (GlobeNewswire) +11.53%
Jun-26-23 04:01PM	GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants (GlobeNewswire)
Jun-20-23 07:00AM	GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients (GlobeNewswire) -6.11%
May-24-23 04:05PM	GeneDx to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-23-23 07:00AM	GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations (GlobeNewswire)
May-22-23 04:05PM	GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +13.10%
May-15-23 09:35AM	Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS) (Zacks)
May-09-23 04:05PM	GeneDx Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -5.65%
May-04-23 07:00AM	GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option (GlobeNewswire)
May-03-23 01:06PM	GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders (GlobeNewswire)
Apr-28-23 06:39PM	Why GeneDx Holdings Stock Lagged the Market Today (Motley Fool) -8.44%
08:10AM	GeneDx Announces Reverse Stock Split (GlobeNewswire)
07:04AM	Daily Vickers Top Buyers & Sellers for 04/28/2023 (Argus Research)
Apr-18-23 04:05PM	GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (GlobeNewswire)
12:55PM	Shareholders Should Be Pleased With GeneDx Holdings Corp.'s (NASDAQ:WGS) Price (Simply Wall St.)
Apr-03-23 08:30AM	GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel (GlobeNewswire)
Mar-22-23 04:36PM	Why Shares of GeneDx Dropped Wednesday (Motley Fool) -16.02% -13.95%
Mar-20-23 09:07PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2022 Earnings Call Transcript (Insider Monkey) +41.30% -9.54%
08:45AM	GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease Diagnostic Odyssey (GlobeNewswire)
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-16-23 08:45AM	GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray (GlobeNewswire)
Mar-14-23 04:16PM	GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-01-23 07:30AM	GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) -5.20%
Feb-28-23 08:30AM	GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting (GlobeNewswire)
Feb-21-23 04:30PM	GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023 (GlobeNewswire) -8.42%
Feb-16-23 08:30AM	GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases (GlobeNewswire) +5.82%
Jan-31-23 04:15PM	GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering (GlobeNewswire) +5.75% -9.44%
Jan-30-23 08:30AM	GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery (GlobeNewswire)
Jan-27-23 06:00AM	GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering (GlobeNewswire) +10.26%
Jan-26-23 04:53PM	GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering (GlobeNewswire)

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Option Exercise	0.00	18,750	0	114,207	Sep 18 04:28 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Sale	37.59	10,501	394,733	103,706	Sep 18 04:28 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	0.00	7,197	0	47,107	Sep 18 04:26 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	37.59	2,635	99,050	44,472	Sep 18 04:26 PM
Kevin Feeley	Officer	Sep 16 '24	Proposed Sale	37.59	2,635	99,050		Sep 16 06:54 PM
Katherine Stueland	Director	Sep 16 '24	Proposed Sale	37.59	10,501	394,733		Sep 16 06:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Option Exercise	0.00	2,462	0	40,805	Sep 11 08:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Sale	33.33	895	29,830	39,910	Sep 11 08:14 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Option Exercise	0.00	6,546	0	99,096	Sep 11 08:10 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Sale	33.33	3,639	121,288	95,457	Sep 11 08:10 PM
Kevin Feeley	Officer	Sep 09 '24	Proposed Sale	33.33	895	29,830		Sep 09 09:03 PM
Katherine Stueland	Officer	Sep 09 '24	Proposed Sale	33.33	3,639	121,288		Sep 09 09:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 01 '24	Option Exercise	0.00	717	0	38,605	Sep 04 08:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 03 '24	Sale	31.71	262	8,308	38,343	Sep 04 08:10 PM
Kevin Feeley	Officer	Sep 03 '24	Proposed Sale	31.71	262	8,308		Sep 03 09:35 PM
OPKO HEALTH, INC.	10% Owner	Aug 19 '24	Sale	34.49	50,000	1,724,520	2,646,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 16 '24	Sale	34.30	50,000	1,714,850	2,696,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 15 '24	Sale	33.08	39,824	1,317,505	2,746,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 12 '24	Sale	33.95	59,787	2,029,811	2,811,783	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 13 '24	Sale	34.76	24,987	868,503	2,786,796	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 08 '24	Sale	31.82	100,000	3,182,380	2,871,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Aug 06 '24	Sale	29.35	12,994	381,427	2,971,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 31 '24	Sale	33.50	88,839	2,976,346	2,984,564	Aug 02 04:21 PM
OPKO HEALTH, INC.	10% Owner	Jul 29 '24	Sale	33.86	50,000	1,692,890	3,073,403	Jul 31 05:03 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '24	Option Exercise	0.00	3,874	0	94,704	Jul 31 04:40 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '24	Sale	33.54	2,154	72,245	92,550	Jul 31 04:40 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Option Exercise	0.00	753	0	38,162	Jul 31 04:39 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	33.54	274	9,190	37,888	Jul 31 04:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 24 '24	Sale	33.72	75,000	2,529,105	3,183,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 26 '24	Sale	33.85	60,000	2,031,258	3,123,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 23 '24	Sale	33.46	75,000	2,509,245	3,258,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 22 '24	Sale	32.61	50,000	1,630,440	3,333,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 19 '24	Sale	32.29	25,000	807,250	3,383,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 17 '24	Sale	32.93	25,000	823,188	3,408,403	Jul 19 06:46 PM
OPKO HEALTH, INC.	10% Owner	Jul 05 '24	Sale	28.24	36,118	1,020,016	3,433,403	Jul 09 04:07 PM
OPKO HEALTH, INC.	10% Owner	Jul 01 '24	Sale	26.63	50,000	1,331,700	3,508,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 02 '24	Sale	29.12	25,000	728,095	3,483,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 03 '24	Sale	28.23	14,082	397,491	3,469,521	Jul 03 04:56 PM
Casdin Eli	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,593	Jun 24 07:04 PM
Leproust Emily M.	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	8,352	Jun 24 05:42 PM
PFENNIGER RICHARD C JR	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	27,664	Jun 24 05:41 PM
RUCH JOSHUA	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,853	Jun 24 05:40 PM
Meister Keith A.	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,205	Jun 24 05:39 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 16 '24	Option Exercise	0.00	7,197	0	40,055	Jun 18 05:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 17 '24	Sale	28.31	2,646	74,908	37,409	Jun 18 05:18 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '24	Option Exercise	0.00	18,750	0	98,513	Jun 18 05:17 PM
Stueland Katherine	Chief Executive Officer	Jun 17 '24	Sale	28.31	7,683	217,506	90,830	Jun 18 05:17 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '24	Option Exercise	0.00	2,462	0	33,753	Jun 11 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	24.92	895	22,303	32,858	Jun 11 04:14 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '24	Option Exercise	0.00	6,546	0	82,415	Jun 11 04:13 PM
Stueland Katherine	Chief Executive Officer	Jun 10 '24	Sale	24.92	2,652	66,088	79,763	Jun 11 04:13 PM
Casdin Capital, LLC	Director	Jun 03 '24	Buy	20.82	100,000	2,081,640	3,063,509	Jun 05 08:45 PM
Casdin Capital, LLC	Director	Jun 04 '24	Buy	22.52	30,000	675,477	3,093,509	Jun 05 08:45 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 01 '24	Option Exercise	0.00	717	0	31,553	Jun 04 04:20 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 03 '24	Sale	20.55	262	5,384	31,291	Jun 04 04:20 PM
Casdin Capital, LLC	Director	May 29 '24	Buy	21.07	40,000	842,604	2,963,509	May 31 05:37 PM
Casdin Capital, LLC	Director	May 24 '24	Buy	20.12	144,196	2,900,906	2,905,205	May 28 08:40 PM
Casdin Capital, LLC	Director	May 28 '24	Buy	20.61	18,304	377,167	2,923,509	May 28 08:40 PM
Casdin Capital, LLC	Director	May 23 '24	Buy	19.59	7,500	146,916	2,761,009	May 28 08:40 PM
Casdin Capital, LLC	Director	May 13 '24	Buy	23.31	50,000	1,165,295	2,753,509	May 15 06:16 PM
PFENNIGER RICHARD C JR	Director	May 02 '24	Option Exercise	0.00	918	0	21,836	May 03 04:04 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '24	Option Exercise	0.00	15,496	0	82,194	Apr 30 04:30 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '24	Sale	11.04	6,325	69,808	75,869	Apr 30 04:30 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Option Exercise	0.00	3,013	0	31,940	Apr 30 04:27 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Sale	11.04	1,104	12,185	30,836	Apr 30 04:27 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 16 '24	Option Exercise	0.00	18,750	0	75,257	Mar 19 04:15 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 18 '24	Sale	10.59	8,559	90,661	66,698	Mar 19 04:15 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 16 '24	Option Exercise	0.00	5,114	0	31,525	Mar 19 04:14 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 18 '24	Sale	10.59	2,008	21,269	29,517	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 16 '24	Option Exercise	0.00	7,197	0	32,180	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	10.59	3,253	34,455	28,927	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 12 '24	Sale	9.21	931	8,574	24,983	Mar 13 04:28 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 12 '24	Sale	9.21	2,618	24,111	56,507	Mar 13 04:24 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 12 '24	Sale	9.21	897	8,261	26,411	Mar 13 04:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 09 '24	Option Exercise	0.00	2,462	0	25,914	Mar 12 05:27 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 09 '24	Option Exercise	0.00	6,547	0	59,125	Mar 12 05:26 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 09 '24	Option Exercise	0.00	2,841	0	27,308	Mar 12 05:25 PM
Casdin Capital, LLC	Director	Mar 04 '24	Buy	8.74	40,000	349,708	2,702,609	Mar 06 07:32 PM
Casdin Capital, LLC	Director	Mar 05 '24	Buy	8.83	900	7,944	2,703,509	Mar 06 07:32 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Jan 19 '24	Option Exercise	0.00	546	0	24,660	Jan 23 04:10 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Jan 22 '24	Sale	3.24	193	625	24,467	Jan 23 04:10 PM
Saad Kareem	Chief Transformation Officer	Jan 03 '24	Sale	2.58	105	271	24,114	Jan 04 05:03 PM
Saad Kareem	Chief Transformation Officer	Jan 01 '24	Option Exercise	0.00	273	0	24,219	Jan 03 04:25 PM
Ryan Jason	Executive Chairman	Dec 31 '23	Option Exercise	0.00	67,780	0	73,614	Jan 03 04:23 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '23	Option Exercise	0.00	18,750	0	64,312	Dec 19 09:26 PM
Stueland Katherine	Chief Executive Officer	Dec 18 '23	Sale	2.16	11,734	25,338	52,578	Dec 19 09:26 PM
Saad Kareem	Chief Transformation Officer	Dec 16 '23	Option Exercise	0.00	5,114	0	25,646	Dec 19 09:25 PM
Saad Kareem	Chief Transformation Officer	Dec 18 '23	Sale	2.16	1,700	3,671	23,946	Dec 19 09:25 PM
Feeley Kevin	Chief Financial Officer	Dec 16 '23	Option Exercise	0.00	7,197	0	25,983	Dec 19 09:24 PM
Feeley Kevin	Chief Financial Officer	Dec 18 '23	Sale	2.16	2,948	6,366	23,035	Dec 19 09:24 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '23	Option Exercise	0.00	6,546	0	49,235	Dec 12 04:06 PM
Stueland Katherine	Chief Executive Officer	Dec 11 '23	Sale	1.61	3,673	5,915	45,562	Dec 12 04:06 PM
Saad Kareem	Chief Transformation Officer	Dec 09 '23	Option Exercise	0.00	2,841	0	21,382	Dec 12 04:05 PM
Saad Kareem	Chief Transformation Officer	Dec 11 '23	Sale	1.61	850	1,369	20,532	Dec 12 04:05 PM
Feeley Kevin	Chief Financial Officer	Dec 09 '23	Option Exercise	0.00	2,462	0	19,694	Dec 12 04:04 PM
Feeley Kevin	Chief Financial Officer	Dec 11 '23	Sale	1.61	908	1,462	18,786	Dec 12 04:04 PM
Feeley Kevin	Chief Financial Officer	Dec 04 '23	Sale	1.77	270	478	17,232	Dec 05 04:45 PM
Ryan Jason	Executive Chairman	Nov 17 '23	Buy	1.54	58,000	89,181	114,742	Nov 20 04:32 PM
Ryan Jason	Executive Chairman	Nov 16 '23	Buy	1.27	56,742	72,187	56,742	Nov 20 04:32 PM

Open in Screener

TNYA

Tenaya Therapeutics Inc

Sep 20 • 04:00PM ET

2.13

Dollar change -0.06
Percentage change -2.74	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

TNYA Tenaya Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN VTWO HRTS IWO IWC AVSC FESM

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	17.22%	Shs Outstand	68.33M	Perf Week	6.50%
Market Cap	168.04M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	-0.14%	Shs Float	65.30M	Perf Month	-26.80%
Income	-120.74M	PEG	-	EPS next Q	-0.37	Inst Own	56.90%	Short Float	7.20%	Perf Quarter	-31.73%
Sales	0.00M	P/S	-	EPS this Y	11.24%	Inst Trans	-5.74%	Short Ratio	11.44	Perf Half Y	-55.44%
Book/sh	1.70	P/B	1.25	EPS next Y	-4.51%	ROA	-62.89%	Short Interest	4.70M	Perf Year	-19.32%
Cash/sh	1.26	P/C	1.69	EPS next 5Y	-	ROE	-74.54%	52W Range	1.66 - 7.01	Perf YTD	-34.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-27.43%	ROI	-82.58%	52W High	-69.61%	Beta	2.39
Dividend TTM	-	Quick Ratio	6.28	Sales past 5Y	0.00%	Gross Margin	-	52W Low	28.31%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	6.28	EPS Y/Y TTM	29.63%	Oper. Margin	0.00%	RSI (14)	37.94	Volatility	7.90% 8.62%
Employees	140	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	19.33
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	24.24%	Payout	-	Rel Volume	1.72	Prev Close	2.19
Sales Surprise	-	EPS Surprise	13.20%	Sales Q/Q	-	Earnings	Aug 08 AMC	Avg Volume	411.21K	Price	2.13
SMA20	-11.71%	SMA50	-26.80%	SMA200	-44.31%	Trades		Volume	706,868	Change	-2.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-24	Initiated	William Blair	Outperform
Nov-30-23	Initiated	Leerink Partners	Outperform	$7
Jun-15-22	Initiated	H.C. Wainwright	Buy	$25

Sep-03-24 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investment Conferences (GlobeNewswire) -5.60%
Aug-08-24 04:05PM	Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.10%
Jun-27-24 05:00PM	Tenaya Therapeutics Announces Research Leadership Updates (GlobeNewswire) +8.09% +5.44%
Jun-18-24 04:30PM	Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit (GlobeNewswire)
May-16-24 12:21PM	Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating (MT Newswires)
07:00AM	Loading…
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-14-24 10:54PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-02-24 05:00PM	Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Mar-26-24 07:19AM	20 Countries with the Highest Heart Disease Deaths Per Capita (Insider Monkey)
Mar-20-24 05:32AM	Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +8.17%
Mar-18-24 10:53PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -6.02%
04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine (GlobeNewswire)
03:02AM	Loading…
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-27-24 04:30PM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-24 09:55AM	Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross? (Zacks) +9.00%
08:30AM	Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications (GlobeNewswire)
Feb-09-24 09:55AM	Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet (Zacks) +10.72%
Feb-08-24 08:00AM	Tenaya Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire) +16.06%
Jan-26-24 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-03-24 08:30AM	Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.28%
Nov-21-23 04:30PM	Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-08-23 04:05PM	Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-26-23 08:30AM	Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) -5.67%
Oct-09-23 08:30AM	Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting (GlobeNewswire)
Oct-05-23 08:30AM	Tenaya Therapeutics Doses First Patient in the MyPeak-1 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire)
Oct-02-23 05:30PM	Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration (GlobeNewswire) -5.24%
Sep-21-23 04:05PM	Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences (GlobeNewswire) +6.06%
04:05PM	Loading…
Aug-31-23 04:05PM	Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire) -5.38%
Aug-09-23 04:05PM	Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Aug-02-23 04:05PM	Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference (GlobeNewswire)
May-30-23 09:06AM	With 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interest (Simply Wall St.)
May-15-23 09:55AM	Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade (Zacks)
May-11-23 08:50AM	Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.65%
May-10-23 04:19PM	Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 08:00AM	Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting (GlobeNewswire) +12.36%
07:09AM	We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-02-23 07:50AM	Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 (GlobeNewswire) -11.30%
Apr-25-23 06:35AM	The 7 Best Biotech Stocks for Personalized Medicine Investors (InvestorPlace) -5.77%
Apr-23-23 04:02PM	3 Penny Stocks to Buy for 100% Returns (InvestorPlace)
Apr-21-23 04:05PM	Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire) +22.79%
Apr-20-23 02:46PM	Why This Nasdaq Stock Caught Fire This Week (Motley Fool) +26.08%
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +17.16%
Mar-08-23 04:01PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.96% -12.57%
Feb-07-23 05:17PM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-26-23 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-09-23 07:00AM	Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones (GlobeNewswire)
Dec-21-22 06:12AM	Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop (Simply Wall St.)
Dec-07-22 04:30PM	Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors (GlobeNewswire)
Dec-02-22 06:36PM	IRobot and Acrivon Stock See Action From Activist Investors (Barrons.com)
Nov-28-22 08:30AM	Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +7.11%
Nov-24-22 05:54AM	Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely (Simply Wall St.)
Nov-23-22 09:00AM	Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-21-22 05:45PM	Tenaya Therapeutics Announces Closing of Public Offering (GlobeNewswire) +9.44%
Nov-17-22 12:39AM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -21.63%
Nov-16-22 04:01PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire) +8.87%
Nov-10-22 04:05PM	Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.81% +30.88%
Nov-04-22 08:00AM	Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022 (GlobeNewswire) -17.87%
Oct-14-22 06:12AM	Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) 17% loss last week hit both individual investors who own 40% as well as institutions (Simply Wall St.)
Oct-04-22 08:30AM	Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress (GlobeNewswire)
Sep-29-22 08:00AM	Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions (GlobeNewswire) -10.42%
07:45AM	Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences (GlobeNewswire)
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Sep-15-22 09:39AM	Harvard Universitys Latest Portfolio: 10 Best Biotech Stock Picks (Insider Monkey)
Sep-06-22 04:05PM	Tenaya Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) -7.24% +8.51%
08:00AM	Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction (GlobeNewswire)
Aug-16-22 09:55AM	Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect? (Zacks) -7.50%
Aug-10-22 04:01PM	Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-06-22 02:00PM	Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure (GlobeNewswire)
Jun-16-22 08:00AM	Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics (Business Wire)
May-20-22 08:30AM	Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference (Business Wire) +18.33%
May-11-22 04:09PM	Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -12.00% +7.12%
May-07-22 09:38AM	We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate (Simply Wall St.)
May-03-22 08:00AM	Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting (Business Wire)
Apr-28-22 08:00AM	Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022 (Business Wire) +5.34%
Mar-24-22 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +12.51%
Mar-23-22 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates (Business Wire) -5.76%
Feb-08-22 12:01PM	Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA) (Zacks)
Feb-04-22 01:03PM	What Is The Ownership Structure Like For Tenaya Therapeutics, Inc. (NASDAQ:TNYA)? (Simply Wall St.) +7.56%
Jan-31-22 08:00AM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +14.40%
Jan-10-22 08:00AM	Tenaya Therapeutics Provides 2022 Business Updates (Business Wire) -6.86%
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... (GuruFocus.com)
Dec-22-21 04:05PM	Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture (Business Wire) +8.98%
Dec-17-21 10:06AM	Harvard University Stock Portfolio: 8 Latest Stock Picks (Insider Monkey)
Nov-22-21 08:00AM	Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors (Business Wire) -8.27%
Nov-19-21 08:00AM	Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference (Business Wire)
Nov-10-21 04:05PM	Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (Business Wire) +5.87%
Nov-05-21 08:36PM	Gene Therapy Is a Huge Opportunity. It Pays to be Patient. (Barrons.com) +6.81%
03:30AM	Testing May Take Awhile, but Gene Therapy Is Poised to Tackle Mass Diseases (Barrons.com)
Nov-03-21 03:41PM	We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate (Simply Wall St.)
Oct-12-21 06:05PM	Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress (Business Wire) -6.02%
Oct-08-21 12:42PM	Most of this year's flood of new Bay Area public companies are 'under water' (American City Business Journals)
Oct-04-21 10:54AM	Buy These 3 New Stocks Before They Jump Over 60%, Say Analysts (TipRanks) +5.78%
Sep-30-21 06:02PM	Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences (Business Wire) +6.49%
Sep-08-21 04:00PM	Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates (Business Wire)
Aug-31-21 08:00AM	Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference (Business Wire) -21.45%
Aug-03-21 04:05PM	Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire) -5.38%
Jul-30-21 05:28PM	Dole Drops in IPO. 7 Biotechs Went Public, Too. (Barrons.com)

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saito Chihiro	SVP, Accounting and Fin. Ops.	Aug 16 '24	Sale	2.89	2,363	6,840	63,241	Aug 19 08:30 PM
Tingley Whittemore	Chief Medical Officer	Aug 16 '24	Sale	2.89	7,428	21,500	107,106	Aug 16 08:26 PM
Ali Faraz	Chief Executive Officer	Aug 16 '24	Sale	2.89	9,748	28,216	188,331	Aug 16 08:25 PM
Whittemore Tingley	Officer	Aug 16 '24	Proposed Sale	2.89	7,428	21,467		Aug 16 08:24 PM
Faraz Ali	Officer	Aug 16 '24	Proposed Sale	2.89	9,748	28,172		Aug 16 08:23 PM
Hoey Timothy	Chief Scientific Officer	Mar 05 '24	Sale	7.00	3,300	23,101	245,346	Mar 06 06:45 PM
Hoey Timothy	Chief Scientific Officer	Feb 20 '24	Sale	5.34	6,569	35,046	236,146	Feb 21 06:05 PM
Hoey Timothy	Chief Scientific Officer	Feb 16 '24	Sale	5.86	4,681	27,431	242,715	Feb 16 08:37 PM
Tingley Whittemore	Chief Medical Officer	Feb 16 '24	Sale	5.86	6,500	38,090	73,534	Feb 16 08:35 PM
PATTERSON LEONE D	Chief Fin. and Bus. Officer	Feb 16 '24	Sale	5.86	5,201	30,478	60,755	Feb 16 08:32 PM
Ali Faraz	Chief Executive Officer	Feb 16 '24	Sale	5.86	6,358	37,258	113,079	Feb 16 08:30 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 12 '24	Buy	4.50	2,222,222	9,999,999	13,599,275	Feb 14 04:15 PM
GOEDDEL DAVID V	Director	Feb 12 '24	Buy	4.50	2,222,222	9,999,999	13,599,275	Feb 14 04:12 PM

LAB

Standard BioTools Inc

WGS

GeneDx Holdings Corp

TNYA

Tenaya Therapeutics Inc

Upgrade your FINVIZ experience